Stryker Corporation $SYK Shares Purchased by Boston Family Office LLC

Boston Family Office LLC lifted its holdings in Stryker Corporation (NYSE:SYK) by 4.5% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 69,380 shares of the medical technology company’s stock after purchasing an additional 2,995 shares during the period. Stryker makes up 1.5% of Boston Family Office LLC’s holdings, making the stock its 15th biggest holding. Boston Family Office LLC’s holdings in Stryker were worth $24,385,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Ieq Capital LLC grew its position in shares of Stryker by 13.3% during the fourth quarter. Ieq Capital LLC now owns 27,123 shares of the medical technology company’s stock worth $9,533,000 after buying an additional 3,184 shares in the last quarter. Vontobel Holding Ltd. grew its position in shares of Stryker by 301.6% during the fourth quarter. Vontobel Holding Ltd. now owns 94,743 shares of the medical technology company’s stock worth $33,299,000 after buying an additional 71,152 shares in the last quarter. First National Bank of Omaha acquired a new position in shares of Stryker during the fourth quarter worth about $1,813,000. Alchemi Wealth LLC acquired a new position in shares of Stryker during the fourth quarter worth about $254,000. Finally, Dynamic Technology Lab Private Ltd grew its position in shares of Stryker by 45.0% during the fourth quarter. Dynamic Technology Lab Private Ltd now owns 3,287 shares of the medical technology company’s stock worth $1,155,000 after buying an additional 1,020 shares in the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the sale, the director owned 1,924,880 shares in the company, valued at $601,005,282.40. This represents a 13.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP M Kathryn Fink sold 3,500 shares of the stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $283.45, for a total transaction of $992,075.00. Following the sale, the vice president owned 177 shares of the company’s stock, valued at $50,170.65. This trade represents a 95.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 323,264 shares of company stock worth $100,659,489 in the last 90 days. Company insiders own 4.60% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on SYK. Sanford C. Bernstein set a $410.00 price target on shares of Stryker in a report on Friday, May 1st. Canaccord Genuity Group lowered their target price on shares of Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Leerink Partners lowered their target price on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research note on Friday, June 5th. Weiss Ratings downgraded shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 4th. Finally, Wall Street Zen cut Stryker from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Sixteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and an average price target of $395.33.

Stryker Stock Performance

NYSE SYK opened at $312.14 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $404.87. The company has a market capitalization of $119.66 billion, a PE ratio of 36.13, a P/E/G ratio of 1.93 and a beta of 0.78. The company has a fifty day moving average of $316.40 and a two-hundred day moving average of $343.97.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. During the same quarter in the prior year, the company earned $2.84 EPS. The business’s revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, analysts expect that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio is currently 40.74%.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.